Potential role of ustekinumab in the treatment of chronic plaque psoriasis

Santo Raffaele Mercuri1, Luigi Naldi21Unit&agrave; di Dermatologia, Istituto di Ricovero e Cura a Carattere Scientifico San Raffaele, Universit&agrave; Vita-Salute, Milano, Italy; 2Centro Studi GISED, Fondazione per la Ricerca Ospedale Maggiore, Unit&agrave; di Dermatologia,...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Santo Raffaele Mercuri, Luigi Naldi
Formato:	article
Lenguaje:	EN
Publicado:	Dove Medical Press 2010
Materias:	Medicine (General) R5-920
Acceso en línea:	https://doaj.org/article/5c6f57a6657543289370aadc5dfe79ac
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:5c6f57a6657543289370aadc5dfe79ac
record_format	dspace
spelling	oai:doaj.org-article:5c6f57a6657543289370aadc5dfe79ac2021-12-02T03:48:23ZPotential role of ustekinumab in the treatment of chronic plaque psoriasis1177-54751177-5491https://doaj.org/article/5c6f57a6657543289370aadc5dfe79ac2010-05-01T00:00:00Zhttp://www.dovepress.com/potential-role-of-ustekinumab-in-the-treatment-of-chronic-plaque-psori-a4407https://doaj.org/toc/1177-5475https://doaj.org/toc/1177-5491Santo Raffaele Mercuri1, Luigi Naldi21Unit&agrave; di Dermatologia, Istituto di Ricovero e Cura a Carattere Scientifico San Raffaele, Universit&agrave; Vita-Salute, Milano, Italy; 2Centro Studi GISED, Fondazione per la Ricerca Ospedale Maggiore, Unit&agrave; di Dermatologia, Ospedali Riuniti, Bergamo, ItalyAbstract: Psoriasis is a relatively common, chronic and disabling skin disease, with an immune-related pathogenesis and a genetic background which may be triggered by several environmental factors including smoking and infections. There is no cure but several treatment options are available. The treatment of psoriasis is far from being satisfactory due to impractical modalities of topical treatment and suboptimal safety profile of the systemic treatments available. In the last few years, parallel to an improved understanding of the disease pathogenesis, there has been a boost in research on new agents for the treatment of psoriasis. Ustekinumab, a monoclonal antibody targeting the p40 subunit of interleukin (IL)-12 and IL-23, is one such new agent. Psoriasis and its management are briefly reviewed before focusing on the evidence for ustekinumab in the treatment of chronic plaque psoriasis through a systematic search of the main registries of ongoing trials up to December 2009. Ustekinumab proved to be very effective short term in the control of clinical manifestations in psoriasis compared with placebo and with etanercept. Long-term and comparative data are still limited. There is a need for continuing research on the long-term effectiveness and safety of the drug.Keywords: ustekinumab, chronic plaque psoriasis Santo Raffaele MercuriLuigi NaldiDove Medical PressarticleMedicine (General)R5-920ENBiologics: Targets & Therapy, Vol 2010, Iss default, Pp 119-129 (2010)
institution	DOAJ
collection	DOAJ
language	EN
topic	Medicine (General) R5-920
spellingShingle	Medicine (General) R5-920 Santo Raffaele Mercuri Luigi Naldi Potential role of ustekinumab in the treatment of chronic plaque psoriasis
description	Santo Raffaele Mercuri1, Luigi Naldi21Unit&agrave; di Dermatologia, Istituto di Ricovero e Cura a Carattere Scientifico San Raffaele, Universit&agrave; Vita-Salute, Milano, Italy; 2Centro Studi GISED, Fondazione per la Ricerca Ospedale Maggiore, Unit&agrave; di Dermatologia, Ospedali Riuniti, Bergamo, ItalyAbstract: Psoriasis is a relatively common, chronic and disabling skin disease, with an immune-related pathogenesis and a genetic background which may be triggered by several environmental factors including smoking and infections. There is no cure but several treatment options are available. The treatment of psoriasis is far from being satisfactory due to impractical modalities of topical treatment and suboptimal safety profile of the systemic treatments available. In the last few years, parallel to an improved understanding of the disease pathogenesis, there has been a boost in research on new agents for the treatment of psoriasis. Ustekinumab, a monoclonal antibody targeting the p40 subunit of interleukin (IL)-12 and IL-23, is one such new agent. Psoriasis and its management are briefly reviewed before focusing on the evidence for ustekinumab in the treatment of chronic plaque psoriasis through a systematic search of the main registries of ongoing trials up to December 2009. Ustekinumab proved to be very effective short term in the control of clinical manifestations in psoriasis compared with placebo and with etanercept. Long-term and comparative data are still limited. There is a need for continuing research on the long-term effectiveness and safety of the drug.Keywords: ustekinumab, chronic plaque psoriasis
format	article
author	Santo Raffaele Mercuri Luigi Naldi
author_facet	Santo Raffaele Mercuri Luigi Naldi
author_sort	Santo Raffaele Mercuri
title	Potential role of ustekinumab in the treatment of chronic plaque psoriasis
title_short	Potential role of ustekinumab in the treatment of chronic plaque psoriasis
title_full	Potential role of ustekinumab in the treatment of chronic plaque psoriasis
title_fullStr	Potential role of ustekinumab in the treatment of chronic plaque psoriasis
title_full_unstemmed	Potential role of ustekinumab in the treatment of chronic plaque psoriasis
title_sort	potential role of ustekinumab in the treatment of chronic plaque psoriasis
publisher	Dove Medical Press
publishDate	2010
url	https://doaj.org/article/5c6f57a6657543289370aadc5dfe79ac
work_keys_str_mv	AT santoraffaelemercuri potentialroleofustekinumabinthetreatmentofchronicplaquepsoriasis AT luiginaldi potentialroleofustekinumabinthetreatmentofchronicplaquepsoriasis
_version_	1718401601918468096

Potential role of ustekinumab in the treatment of chronic plaque psoriasis

Ejemplares similares